Yüklüyor......
Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
AIMS: Two anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. We reviewed data from Phase 3 studies to evaluate the efficacy and safety of these antibodies. MET...
Kaydedildi:
| Yayımlandı: | Br J Clin Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5099564/ https://ncbi.nlm.nih.gov/pubmed/27478094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13066 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|